Aranzazu Recio Linares
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aranzazu Recio Linares has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Alberto Barasoain Millán
Division of Pediatric Endocrinology, Department of Pediatrics, Hospital Universitario Fundación de Alcorcón, Madrid, Spain
1 shared publicationCarolina Bezanilla López
Division of Pediatric Endocrinology, Department of Pediatrics, Hospital Universitario Fundación de Alcorcón, Madrid, Spain
1 shared publicationElia Pérez Pérez Fernández
Research Unit, Hospital Universitario Fundación de Alcorcón, Madrid, Spain
1 shared publicationFidel Cano Cano Dorao
Department of Radiology, Hospital Universitario Fundación de Alcorcón, Madrid, Spain
1 shared publicationGonzalo Botija
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Hospital Universitario Fundación de Alcorcón, Madrid, Spain
1 shared publication- Gonzalo Botija
Pediatric Gastroenterology Unit Hospital Universitario Fundación Alcorcón Madrid Spain
1 shared publication
Latest Publications
- 4 June 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (7)
Hepatic steatosis in pediatric obesity: association with cardiometabolic profile and considerations regarding alanine aminotransferase screening
Hepatic steatosis is the most common chronic liver disease in children with obesity and is associated with an adverse cardiometabolic profile. This study aimed to estimate the prevalence of cardiometabolic risk factors and ultrasound-guided attenuation parameter (UGAP)-diagnosed hepatic steatosis in children with obesity, evaluate variables associated with steatosis, and explore the diagnostic performance of alanine aminotransferase (ALT). This single-center, cross-sectional study included 91 children aged ≥ 9 years with obesity recruited from pediatric endocrinology and gastroenterology outpatient clinics between July 2023 and July 2025. Anthropometric, blood pressure, biochemical, and UGAP measurements were collected. Hepatic steatosis was defined as UGAP ≥ 0.680 dB/cm/MHz. Elevated ALT was defined as ≥ 44 U/L in females and ≥ 52 U/L in males. Associations with hepatic steatosis were assessed using Poisson regression. The prevalence of UGAP-diagnosed hepatic steatosis was 28.6%. Higher BMI z-score, larger waist circumference, elevated ALT, arterial hypertension, dyslipidemia, insulin resistance, and metabolic syndrome were significantly associated with hepatic steatosis. Elevated ALT showed low sensitivity (19.2%) and high specificity (93.8%) for detecting hepatic steatosis. ALT discriminatory performance differed by sex, with an AUC of 0.816 in females and 0.582 in males. Exploratory ALT cutoffs showed limited clinical applicability, particularly in males because of very low specificity. Children with obesity and UGAP-diagnosed hepatic steatosis showed a more unfavorable cardiometabolic profile. ALT alone may miss a substantial proportion of children with hepatic steatosis, supporting the need for improved screening strategies. • Pediatric hepatic steatosis is associated with an adverse cardiometabolic profile in children with obesity. • Screening strategies based on ALT and imaging techniques show variable diagnostic performance in pediatric populations. • UGAP-diagnosed hepatic steatosis in children with obesity was associated with an unfavorable cardiometabolic profile in a Spanish secondary-care cohort. • ALT showed sex-specific differences and limited usefulness as a standalone screening tool for hepatic steatosis, particularly in males, when UGAP was used as the reference method.
- 4 June 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (7)
Hepatic steatosis in pediatric obesity: association with cardiometabolic profile and considerations regarding alanine aminotransferase screening
Hepatic steatosis is the most common chronic liver disease in children with obesity and is associated with an adverse cardiometabolic profile. This study aimed to estimate the prevalence of cardiometabolic risk factors and ultrasound-guided attenuation parameter (UGAP)-diagnosed hepatic steatosis in children with obesity, evaluate variables associated with steatosis, and explore the diagnostic performance of alanine aminotransferase (ALT). This single-center, cross-sectional study included 91 children aged ≥ 9 years with obesity recruited from pediatric endocrinology and gastroenterology outpatient clinics between July 2023 and July 2025. Anthropometric, blood pressure, biochemical, and UGAP measurements were collected. Hepatic steatosis was defined as UGAP ≥ 0.680 dB/cm/MHz. Elevated ALT was defined as ≥ 44 U/L in females and ≥ 52 U/L in males. Associations with hepatic steatosis were assessed using Poisson regression. The prevalence of UGAP-diagnosed hepatic steatosis was 28.6%. Higher BMI z-score, larger waist circumference, elevated ALT, arterial hypertension, dyslipidemia, insulin resistance, and metabolic syndrome were significantly associated with hepatic steatosis. Elevated ALT showed low sensitivity (19.2%) and high specificity (93.8%) for detecting hepatic steatosis. ALT discriminatory performance differed by sex, with an AUC of 0.816 in females and 0.582 in males. Exploratory ALT cutoffs showed limited clinical applicability, particularly in males because of very low specificity. Children with obesity and UGAP-diagnosed hepatic steatosis showed a more unfavorable cardiometabolic profile. ALT alone may miss a substantial proportion of children with hepatic steatosis, supporting the need for improved screening strategies. • Pediatric hepatic steatosis is associated with an adverse cardiometabolic profile in children with obesity. • Screening strategies based on ALT and imaging techniques show variable diagnostic performance in pediatric populations. • UGAP-diagnosed hepatic steatosis in children with obesity was associated with an unfavorable cardiometabolic profile in a Spanish secondary-care cohort. • ALT showed sex-specific differences and limited usefulness as a standalone screening tool for hepatic steatosis, particularly in males, when UGAP was used as the reference method.
- Open Access
- 20 February 2026
- Published by Elsevier in Anales de Pediatría
Infección por Helicobacter pylori y reflujo duodenogástrico
- 20 February 2026
- Published by Elsevier in Anales de Pediatría
Open AccessInfección por Helicobacter pylori y reflujo duodenogástrico